Brief: Precigen Reports Durable Responses With Papzimeos in Recurrent Respiratory Papillomatosis
13/10/2025 12:11
Oct 13 (Reuters) - Precigen Inc PGEN.O: PRECIGEN ANNOUNCES LONG-TERM FOLLOW-UP RESULTS HIGHLIGHTING ONGOING DURABLE COMPLETE RESPONSES AFTER TREATMENT WITH PAPZIMEOS, THE FIRST AND ONLY FDA-APPROVED THERAPY FOR ADULTS WITH RECURRENT RESPIRATORY PAPILLOMATOSIS PRECIGEN INC - 83% OF RESPONDERS SHOW CONTINUED COMPLETE RESPONSE AFTER 36 MONTHS PRECIGEN INC - SURGERY REDUCTION OBSERVED IN 95% OF PATIENTS BY YEAR 3 PRECIGEN INC - NO NEW SAFETY EVENTS OBSERVED DURING LONG-TERM FOLLOW-UP Source text: ID:nPn1Sk4yHa Further company coverage: PGEN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Precigen
See all newsBrief: Precigen Receives FDA Platform Technology Designation For Adenoverse Platform
Precigen, Inc. reports results for the quarter ended June 30 - Earnings Summary
Precigen posts quarterly profit as PAPZIMEOS sales surge
Precigen Inc expected to post a loss of 1 cent a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Advanced Energy, Bel Fuse, Cerebras